Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 23, Issue 6, Pages 1317-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2009.09.002
Keywords
IVIG; IV anti-D; ITP; Thrombocytopenia; FcRIlb; Immunemodulation
Categories
Ask authors/readers for more resources
Intravenous immunoglobulin and intravenous anti-D are common therapies in the management of patients with immune thrombocytopenia (ITP). Both are pooled plasma products and both result in an increase in the platelet count in approximately 60% to 70% of patients with ITP. Despite immediate increases in the platelet count, the duration of response is limited, with platelet increments lasting between 2 and 4 weeks. Infusion reactions are common but adverse events rare. Although responses are similar, human and murine data suggest that the mechanisms of action of these treatments are complex and likely different.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available